130 related articles for article (PubMed ID: 38687953)
1. Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
J Clin Oncol; 2024 Apr; ():JCO2400711. PubMed ID: 38687953
[No Abstract] [Full Text] [Related]
2. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
[No Abstract] [Full Text] [Related]
4. Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.
Takahashi N; Shimizu C; Shimomura A; Toi M
Transl Breast Cancer Res; 2022; 3():3. PubMed ID: 38751527
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
[TBL] [Abstract][Full Text] [Related]
9. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey Emilio J
Farm Hosp; 2024; 48(2):75-78. PubMed ID: 37735004
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey EJ
Farm Hosp; 2024; 48(2):T75-T78. PubMed ID: 38114413
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
Royce M; Osgood C; Mulkey F; Bloomquist E; Pierce WF; Roy A; Kalavar S; Ghosh S; Philip R; Rizvi F; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
J Clin Oncol; 2022 Apr; 40(11):1155-1162. PubMed ID: 35084948
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
Davie A; Traoré S; Giovannitti M; Pompilio G; Lambton M; Cakar E; Chatterjee A
Glob Reg Health Technol Assess; 2023; 10():62-69. PubMed ID: 37811343
[TBL] [Abstract][Full Text] [Related]
14. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Goetz MP; Cicin I; Testa L; Tolaney SM; Huober J; Guarneri V; Johnston SRD; Martin M; Rastogi P; Harbeck N; Shahir A; Wei R; André V; Rugo HS; O'Shaughnessy J
NPJ Breast Cancer; 2024 Apr; 10(1):34. PubMed ID: 38671001
[TBL] [Abstract][Full Text] [Related]
15. Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
Fung S; Blair HA
Target Oncol; 2023 Mar; 18(2):287-294. PubMed ID: 36826463
[TBL] [Abstract][Full Text] [Related]
16. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
[TBL] [Abstract][Full Text] [Related]
17. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
18. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J
Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
Sammons S; Moore H; Cushman J; Hamilton E
Expert Rev Anticancer Ther; 2022 Aug; 22(8):805-814. PubMed ID: 35737886
[TBL] [Abstract][Full Text] [Related]
20. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.
Magnoni F; Corso G; Maisonneuve P; Bianchi B; Accardo G; Sangalli C; Massari G; Rotili A; Nicosia L; Pesapane F; Montagna E; Mazzarol G; Galimberti V; Veronesi P; Curigliano G
EClinicalMedicine; 2024 May; 71():102552. PubMed ID: 38545425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
